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Summary A case-control study was conducted to assess maternal hormonal factors associated with increased
risk of bearing a cryptorchid son. Serum samples were collected during the first trimester of pregnancy from
participants in the US Collaborative Perinatal Study. Twenty-five mothers of normal offspring (controls) were
individually matched on medical center, age, parity, weight and length of gestation at the time of sampling to
women bearing sons who had a diagnosis of cryptorchidism at one year of age or older. Compared with
controls, mothers of cryptorchid sons (cases) had significantly greater percentages of non-protein bound
(P=0.010) and albumin-bound (P=0.014) estradiol during the first trimester of the index pregnancy. On
average, cases had 16% more bioavailable oestradiol than controls. Levels of human chorionic gonadotropin,
testosterone, non-protein bound testosterone and sex-hormone binding globulin did not differ between the
two groups. The data presented support the hypothesis that cryptorchidism results from elevated maternal
oestrogen levels early in pregnancy.
Cryptorchidism, a relatively common abnormality of the
male genitourinary system, is the major known risk factor
for testicular cancer (Henderson et al., 1979; Schottenfeld et
al., 1980; Depue et al., 1983). Although the causes of both
testicular cancer and cryptorchidism are largely unknown,
their epidemiology (Depue et al., 1983; Swerdlow et al.,
1983; Depue, 1984; Brown et al., 1986) and the higher rates
of urogenital developmental anomalies, including crypt-
orchidism, in testicular cancer cases and male family
members of testicular cancer cases (Tollerud et al., 1985)
suggest common aetiological factors.
Higher maternal levels of oestrogen in early pregnancy
may play a role in the aetiology of cryptorchidism. Testicu-
lar maldescent can be produced experimentally in animals by
administering diethylstilbestrol (DES) or other forms of
oestrogen during gestation (Jean, 1973; McLachlin et al.,
1975; Nomura & Kanzaki, 1977; Yasuda et al., 1985). A
number of clinical studies have found an increased frequency
of cryptorchidism in males with a history of DES exposure
in utero (Cosgrove et al., 1977; Whitehead & Leiter, 1981).
In epidemiologic studies of cryptorchidism, the abnormality
has been associated with maternal use of exogenous oestro-
gens including DES during gestation (Gill et al., 1979;
Depue, 1984).
High maternal body weight also has been associated with
an increased risk of cryptorchidism (Depue, 1984). Increased
levels of 'free' (non-protein bound) oestradiol (E2) are
associated with high maternal body weight (Bernstein et al.,
1986). In pregnancy, plasma E2 is mostly bound to sex-
hormone binding globulin (SHBG) and the remainder to
albumin, with only about 1% being free (Anderson, 1974). It
is generally accepted that the non-protein bound E2 is free to
reach intracellular receptors, and there is now increasingly
persuasive evidence that the E2 bound to albumin may also
be 'bioavailable' (Pardridge, 1986). The observed effect of
high maternal body weight on risk of cryptorchidism may
result from higher maternal levels of bioavailable E2.
Another possible mechanism that has been suggested is
that higher maternal E2 levels exert an effect on testicular
descent by lowering testosterone (T) levels in the foetus
(Hadziselimovic & Herzog, 1980). If this is an important
mechanism, high maternal T levels may protect against
cryptorchidism.
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Davies et al. (1986) recently suggested that impaired
placental function may play a role in cryptorchidism. They
theorized that when levels of human chorionic gonadotropin
(hCG) are reduced, there may be changes in foetal testicular
function and hence an increased risk of maldescent.
The purpose of the present study was to determine
whether first trimester maternal hormone levels in the index
pregnancy differ between mothers of cryptorchid sons (cases)
and mothers of 'normal' offspring (controls). Here, we
compare levels of free and bound E2, free and bound T,
SHBG and hCG.
Subjects and methods
Subjects
Study subjects were participants in the Collaborative Perina-
tal Project of the National Institute of Neurological and
Communicative Disorders and Stroke (Bethesda, MD, USA),
a prospective study conducted to identify etiologic factors
related to adverse pregnancy outcome (Niswander &
Gordon, 1972). In this project, more than 55,000 pregnancies
were registered at 12 university-affiliated medical centers in
the United States between 1958 and 1965. The majority of
these pregnancies were beyond 20 weeks (measured from day
I of the last menstrual period) at the time of registration.
Blood samples were collected at each prenatal visit. The
samples have been stored at a central repository at -20"C.
A detailed medical history was obtained from each partici-
pant and detailed obstetric and delivery records were kept.
In the Perinatal Project, offspring were examined at birth,
4 months, I year and 7 years of age; records were kept on
congenital abnormalities and development. White women
bearing sons who had a diagnosis of cryptorchidism at the I
year or 7 year examination were considered eligible as 'cases'
for the present study: no woman who had taken hormones
or had experienced severe nausea or vomiting during the
index pregnancy was considered eligible. There were 25 such
women with sera available for evaluation who registered
with the Perinatal Project by week 13 (measured from day 1
of the last menstrual period) of the relevant pregnancy. One
control woman was individually matched to each case by
medical center, race, parity, weight (within 4kg), age at time
of index pregnancy (within 5 years), and length of gestation
at registration and sampling (within 11 days). Twenty-two of
the 25 control mothers bore male offspring; for the remain-
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ing 3 cases, we were forced to use mothers of female
offspring. All of the offspring of control mothers were
followed for 7 years with no malformations noted.
Assays
Serum samples were shipped on dry ice to London (JM) for
measurement of total E2, percentage of E2 bound to SHBG,
percentage of free E2, total T, percentage of free T, SHBG,
and hCG. The identity of specimens was not known to the
processing laboratory. The only identifier was a coded
number unique for each submission of a specimen.
Ostradiol levels were measured by direct radioimmuno-
assay (Steranti Research Limited, St Albans, Herts., UK).
The percentage of free E2 was measured by centifugal-
ultrafiltration-dialysis in undiluted serum at 37°C (Ham-
mond et al., 1980). The percentage of E2 which was bound
to albumin was calculated from the measured free E2 (%) in
native serum and the free E2 (%) observed in serum which
had been heated at 60°C for I h (Hammond et al., 1982;
Siiteri et al., 1982). SHBG was measured by a liquid phase
immunoradiometric assay (Hammond et al., 1985) using
antisera kindly supplied by Dr G.L. Hammond, University
of Western Ontario, Canada. Levels of free T were measured
by the 'Coat-A-Count' free testosterone kit method (Diag-
nostic Products Corporation, Los Angeles, CA, USA) and
total T by direct assay using the Gamma-B 1251-testosterone
kit (RIA UK, Washington, Tyne and Wear, UK). hCG was
assayed by the double antibody kit method supplied by
Diagnostic Products Corporation, Los Angeles, CA, USA.
Statistical analysis
The amount of free E2 was computed as the product of total
E2 and the percentage of free E2; other amounts were
calculated in a similar manner. Hormone and SHBG values
followed a lognormal distribution and logarithmic (base 10)
values of these variables were used in all statistical analyses.
Statistical analyses were performed using paired t tests and
repeated measures analysis of covariance. Adjustments for
differences in length of gestation assumed a linear relation-
ship between length of gestation and log hormone values.
One-sided P values are presented for these comparisons
because the hormonal hypotheses to be tested predicted
higher total (and bioavailable) E2 which would be the
stimulus for greater amounts of SHBG (Pearlman et al.,
1967) and lower T and hCG levels.
Results
One case-control pair was eliminated from the analyses that
follow because the control's values for hCG and E2 were low
and not consistent with a 7 week gestation. Inclusion of this
pair would have accentuated the differences presented below.
Relevant pregnancy characteristics and assay results for
the remaining 24 matched case-control pairs are presented in
Table I. Cases and controls were closely matched on age,
weight and length of gestation at sampling. Subjects ranged
in age from 18 to 39. Length of gestation at the time of
sampling ranged from 46 to 93 days from the first day of the
last menstrual period.
Although total E2 concentrations of cases and controls did
not differ, cases had significantly greater percentages of free
E2 (P=0.010) and of albumin-bound E2 (P=0.014) than
controls. The E2 fractions that are considered biologically
available were correspondingly greater in cases than in
controls. On average, the cases had 16% more free E2
(P=0.066) and 16% more albumin-bound E2 (P=0.038)
than controls. Levels of SHBG in cases and in controls were
not significantly different. Total and free T levels did not
differ significantly between cases and controls. Although not
statistically significant, hCG levels were 15% higher in cases
than in control women and this difference was consistently
found across gestational ages.
Adjusting for length of gestation, parity, and, in the case
of SHBG, for weight had no effect on the results presented
in Table I. Results of analyses restricted to the 21 matched
pairs in which all of the offspring were male did not alter the
results presented.
Table I Relevant pregnancy characteristics (±s.d.) of study subjects and geometric mean hormone levels
(log 1O+s.d.) in early gestation for 24 mothers ofcryptorchid sons (cases) and 24 mothers of normal offspring
(controls)
Variable Cases Controls P-valuea
Age (yr)
Weight (kg)
Days of gestation
at sampling
Weeks of gestation
at birth
Birth weight of
offspring (g)
Oestradiol
Total (ngdl 1)
Binding percentages
SHBG-boundb
Albumin-boundb
Free
Non-SHBG bound (ngdl-1)
Albumin-boundb
Free
Testosterone
Total (ngdl 1
Free (ngdl -
SHBG (nmolP1')
hCG (IUml-1)
25.7 (± 5.4)
60.2 (+17.1)
71.6 (±10.9)
39.9 (±2.2)
3090 (±571)
969.2 (2.986+0.118)
61.3 (±9.8)
37.6 (+9.6)
1.2 (±0.2)
348.1 (2.542+0.155)
11.0 (1.042+0.157)
125.9 (2.100+0.183)
3.4 (0.530+0.128)
212.3 (2.327+0.222)
85.1 (1.930+0.278)
25.0 (± 5.0)
59.1 (±13.0)
70.9 (±10.4)
40.0 (±2.0)
3313 (±632)
949.8 (2.978+0.167)
66.5 (± 8.4)
32.5 (±8.3)
1.0 (±0.2)
300.0 (2.477+0.163)
9.5 (0.977+0.161)
127.1 (2.104+0.204)
3.6 (0.561 +0.130)
205.8 (2.313+0.216)
74.2 (1.870+0.273)
aPaired t-test, 2-sided P values reported for pregnancy characteristics and 1-sided P values reported for
hormone and protein levels; bbased on 22 pairs (insufficient samples available for 2 cases).
0.080
0.497
0.497
0.719
0.146
0.413
0.014
0.014
0.010
0.038
0.066
0.471
0.219
0.392
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Discussion
It is commonly accepted that testicular descent is under
hormonal control (Hutson & Donahoe, 1986). We have
previously hypothesized that excess endogenous maternal
oestrogens play a role in the risk of cryptorchidism. In this
study, we have found significantly greater percentages of free
and albumin-bound E2 in the first trimester sera of mothers
bearing cryptorchid sons. This resulted in greater concen-
trations of non-SHBG bound E2 in these pregnancies.
Burton et al. (1987) found no significant difference in
maternal E2 levels between mothers of cryptorchid boys and
control mothers. They did not consider bioavailable E2.
Two theories have been proposed to explain the effect of
oestrogen on testicular descent. Hadziselimovic & Herzog
(1980) proposed that the mechanism responsible for this
effect is the suppression of foetal androgen secretion by
oestrogen. It has, however, recently been shown in studies of
hypogonadal mice that foetal testosterone production in
early gestation is not relevant to the aetiology of crypt-
orchidism (Charlton, 1986; Grocock et al., 1988). Current
thinking (Hutson & Donahoe, 1986) considers a biphasic
model for the hormonal control of testicular descent. In this
model, separate hormones and mechanisms control the two
stages of descent, the initial transabdominal phase, occurring
prior to the twelfth week of gestation in man, and the
transinguinal phase, occurring during the third trimester in
man. The first stage is thought to be regulated by mullerian
inhibiting substance, whereas the second, later stage is
androgen dependent. Based on animal data, it appears that
estrogens inhibit mullerian inhibiting substance (Newbold et
al., 1984; Hutson et al., 1985) and cause atrophy of the
gubernaculum (Wensing, 1973; Grocock et al., 1988).
Although cryptorchidism is a risk factor for testis cancer,
the risk of testis cancer is not confined to the involved testis
in unilaterally cryptorchid men (Depue et al., 1983). Crypt-
orchidism may be secondary to oestrogen inhibition of
mullerian inhibiting substance resulting in intra-abdominal
arrest of descent. Excess maternal oestrogen may mediate
risk of testicular cancer more directly by interrupting the
progression of primitive germ cells to mature germ cells.
These primitive cells, persisting into puberty, would multiply
under stimulation by gonadotropins and give rise to germ
cell tumours of a variety of histological types depending on
their particular stage of 'developmental arrest' (Henderson et
al., 1983).
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